☆ 4.2 Article

Acquired B-cell deficiency secondary to B-cell-depleting therapies

JOURNAL OF IMMUNOLOGICAL METHODS (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Biochemistry & Molecular Biology

B cell-activating factor and its targeted therapy in autoimmune diseases

Yidan Zhang et al.

Summary: B cells play a pivotal role in autoimmune diseases, and B cell-activating factor (BAFF) is key in driving autoreactive B cell response. Increased BAFF levels have been observed in patients with autoimmune diseases and mouse models where autoantibody production is prominent. Recent clinical studies have shown BAFF as a potential therapeutic target for treating autoimmune diseases.

CYTOKINE & GROWTH FACTOR REVIEWS (2022)

添加到收藏夹

Article Allergy

Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees

Iris M. Otani et al.

Summary: Secondary hypogammaglobulinemia is characterized by reduced immunoglobulin levels due to decreased antibody production or increased loss. It is important to determine whether the hypogammaglobulinemia is secondary or primary for evaluation and management. Patients with a history of immunosuppressive medications or conditions associated with SHG require thorough investigation to determine the underlying causes and devise effective treatment plans. When iatrogenic causes cannot be removed or underlying conditions cannot be reversed, monitoring for clinical infections, supportive antimicrobials, and immunoglobulin replacement therapy may be considered.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)

添加到收藏夹

Article Clinical Neurology

Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for > 4 years in the N-MOmentum trial

Mary Rensel et al.

Summary: Long-term inebilizumab treatment in AQP4-IgG-seropositive patients with neuromyelitis optica spectrum disorder showed a low annualized attack rate, stable disability scores, and good tolerability. Levels of Immunoglobulin G decreased over time, but no clear correlation with severe infections was determined. The study continues to support the use of inebilizumab for this disorder, and suggests potential enhanced efficacy with longer treatment duration.

MULTIPLE SCLEROSIS JOURNAL (2022)

添加到收藏夹

Review Clinical Neurology

Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases

Panos Stathopoulos et al.

Summary: B cells play an important role in the etiology of autoimmune neurological disorders, acting as antigen-presenting cells and regulating the immune response. Depletion of B cells has become a promising treatment strategy. This paper summarizes the basic aspects of B cell biology, discusses the roles of B cells in neurological autoimmunities, and highlights the efficacy and practical considerations of anti-B cell therapies in different neurological disorders.

NEUROTHERAPEUTICS (2022)

添加到收藏夹

Article Clinical Neurology

AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder

Romain Marignier et al.

Summary: This study reported the outcomes of AQP4- participants in NMOSD. Only 36% of AQP4 screened participants were considered eligible for randomization. The study evaluated MOG-IgG serology and annualized attack rates, and assessed efficacy by comparing pre-study and on-study AARs.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2022)

添加到收藏夹

Review Oncology

Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma

James A. Davis et al.

Summary: This article summarizes the background, clinical trials, and place in therapy for the first two anti-CD19 monoclonal antibodies that have been recently FDA approved for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). These novel therapies have started to change management strategies and outcomes for these patients. However, the place in therapy and sequencing of these agents can present a challenge to prescribers, especially for patients being evaluated for CD19 targeting CAR T-cell therapy.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2022)

添加到收藏夹

Letter Hematology

CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma

Akinao Okamoto et al.

BLOOD ADVANCES (2022)

添加到收藏夹

Review Clinical Neurology

Anti-CD20 therapies for multiple sclerosis: current status and future perspectives

Monica Margoni et al.

Summary: Multiple sclerosis is a chronic disease affecting the central nervous system, and recent advancements in immune pathophysiology have led to the identification of selective B-cell-depleting therapies like anti-CD20 monoclonal antibodies, which have shown strong efficacy and safety in treating MS. This has expanded the therapeutic options for both relapsing and progressive MS patients, highlighting the important role of B cells in the disease process.

JOURNAL OF NEUROLOGY (2022)

添加到收藏夹

Review Immunology

CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma

Massimiliano Gambella et al.

Summary: Surgical resection, chemotherapy, and radiotherapy have been the primary cancer treatments for a long time. Recently, immune checkpoint inhibitors and adoptive cell therapies have emerged as promising alternatives. These therapies aim to activate and utilize the patient's immune system to fight against cancer cells, and have shown remarkable results.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Review Cell Biology

CD20+ T cells: an emerging T cell subset in human pathology

Adrian Y. S. Lee

Summary: Although CD20 is primarily known as a B cell marker, it has been observed in a subset of T cells as well. These CD20(+)T cells appear to express more inflammatory cytokines and markers of effector function compared to CD20(-)T cells. The current understanding is that CD20 may be acquired from B cells through trogocytosis. CD20(+)T cells can be found in various diseases including autoimmune diseases, malignancies, and HIV infections. Multiple sclerosis is one of the best-studied diseases where CD20(+)T cells are found and therapeutic interventions targeting CD20 have shown promise in depleting these cells.

INFLAMMATION RESEARCH (2022)

添加到收藏夹

Article Infectious Diseases

Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19

Yusuke Miyazato et al.

Summary: This case describes a COVID-19 patient with humoral immunodeficiency who experienced multiple relapses due to anti-CD20 monoclonal antibody treatment. The patient was successfully treated with casirivimab/imdevimab and developed neutralizing antibodies. This suggests that monoclonal antibodies have therapeutic and prophylactic value in patients with humoral immunodeficiency.

JOURNAL OF INFECTION AND CHEMOTHERAPY (2022)

添加到收藏夹

Review Immunology

Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients

Romy Mosch et al.

Summary: This review discusses ADA formation of mAbs and its clinical impact, as well as proposes the use of HLA haplotypes as biomarkers to predict patients' susceptibility to ADA formation.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Rheumatology

New-onset hypogammaglobulinaemia and infectious complications associated with rituximab use in childhood-onset rheumatic diseases

Mei Sing Ong et al.

Summary: Rituximab treatment for childhood-onset rheumatic diseases can lead to hypogammaglobulinaemia and infectious complications, with steroid therapy and age as significant risk factors.

RHEUMATOLOGY (2022)

添加到收藏夹

Article Immunology

Dysregulation in B-cell responses and T follicular helper cell function in ADA2 deficiency patients

Francesca Schena et al.

Summary: DADA2 patients show decreased memory B cells, particularly in class switch memory, and an expansion of CD21(low)B cells. In vitro stimulated B lymphocytes can secrete nonfunctional ADA2 protein, suggesting a cell intrinsic defect leading to impaired B-cell proliferation and differentiation. Additionally, CD4(+) and CD8(+) T cells are reduced, while circulating T follicular helper cells are significantly increased but have impaired IL-21 production, potentially contributing to impaired B cell help.

EUROPEAN JOURNAL OF IMMUNOLOGY (2021)

添加到收藏夹

Article Rheumatology

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

Jerome Avouac et al.

Summary: Rituximab therapy is associated with more severe COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases, and should be prescribed with caution.

LANCET RHEUMATOLOGY (2021)

添加到收藏夹

Article Transplantation

Rituximab Desensitization in Liver Transplant Recipients With Preformed Donor-specific HLA Antibodies: A Japanese Nationwide Survey

Nobuhisa Akamatsu et al.

Summary: Rituximab induction was well tolerated among DSA-positive liver transplant recipients with a dose >300 mg/m(2) observed to achieve a lower incidence of antibody-mediated rejection. The study found a higher rate of infusion-related adverse drug reactions but all of them were mild and self-limiting, with no severe adverse events associated with rituximab reported.

TRANSPLANTATION DIRECT (2021)

添加到收藏夹

Article Rheumatology

Incidence, Clinical Features, and Outcomes of Late-Onset Neutropenia From Rituximab for Autoimmune Disease

Reza Zonozi et al.

Summary: Late-onset neutropenia (LON) is a common and often incidental complication of rituximab treatment, with systemic lupus erythematosus and combination therapy with cyclophosphamide being independently associated with an increased risk of LON. Most episodes are asymptomatic, but fever and sepsis can complicate a significant proportion of cases. Filgrastim is commonly used for treatment, and recurrence of LON can occur in a subset of patients following rituximab rechallenge. Vigilant monitoring is warranted due to the potential for serious infections.

ARTHRITIS & RHEUMATOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus A Randomized Controlled Trial

Muhammad Shipa et al.

Summary: In patients with refractory systemic lupus erythematosus (SLE), the use of belimumab following rituximab significantly reduced serum IgG anti-dsDNA antibody levels and decreased the risk of severe disease flares, suggesting the potential for this combination as a therapeutic strategy.

ANNALS OF INTERNAL MEDICINE (2021)

添加到收藏夹

Article Surgery

Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): A nationwide cohort study

Laura N. Walti et al.

Summary: Posttransplant lymphoproliferative disorder (PTLD) is a serious complication of solid organ transplantation (SOT), mostly associated with Epstein-Barr virus (EBV) infection. The role of antiviral prophylaxis or rituximab therapy in preventing PTLD in SOT recipients is controversial. However, receiving rituximab as induction treatment was associated with a significantly longer PTLD-free survival time in patients.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

添加到收藏夹

Article Immunology

Intrinsic Defects in B Cell Development and Differentiation, T Cell Exhaustion and Altered Unconventional T Cell Generation Characterize Human Adenosine Deaminase Type 2 Deficiency

Jin Yan Yap et al.

Summary: The study conducted in-depth immunophenotyping and functional analysis of human lymphocytes in ten patients with DADA2, revealing defects in B cell differentiation, impaired memory T cell differentiation, and increased inflammatory monocytes and immature NK cells. The findings shed light on the complex immune phenotype of DADA2 and suggest the need for targeted therapy to prevent viral infections and excessive inflammation in these patients.

JOURNAL OF CLINICAL IMMUNOLOGY (2021)

添加到收藏夹

Article Rheumatology

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Anja Strangfeld et al.

Summary: Factors associated with COVID-19-related death in people with rheumatic diseases include age, sex, comorbidities, disease activity, and specific medications. Adequate disease control with disease-modifying anti-rheumatic drugs (DMARDs) without increasing glucocorticoid dosages is important, while caution may be required with certain medications such as rituximab and sulfasalazine.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Multidisciplinary Sciences

CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties

Martijn Vlaming et al.

Summary: CD20-positive T cells play a significant role in both autoimmunity and cancer, with studies showing that they possess various functional properties such as enhanced activation and reduced transmigration.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Letter Rheumatology

SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response

Michael Markus Bonelli et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Review Immunology

COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge

Anna Furlan et al.

Summary: The study demonstrates significant effects of B cell-depleting agents on adaptive immunity, which should be considered in the selection of SARS-CoV-2 diagnostics and guiding therapeutic approaches. Combination therapeutic strategies may play a crucial role in the setting of B cell immune deficiencies.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Allergy

Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients

Roxane Labrosse et al.

Summary: The study revealed a high prevalence of hypogammaglobulinemia in children receiving rituximab treatment, with low IgG levels associated with an increased risk of serious infections. Underlying primary immunodeficiencies were relatively common in pediatric patients receiving rituximab.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

添加到收藏夹

Article Rheumatology

Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

Jeffrey A. Sparks et al.

Summary: This study investigated the baseline use of biologic or targeted synthetic disease-modifying antirheumatic drugs and COVID-19 outcomes in patients with rheumatoid arthritis. The results showed that patients treated with rituximab or Janus kinase inhibitors were associated with worse COVID-19 severity, emphasizing the need for prioritizing risk mitigation strategies for these individuals.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Review Pediatrics

Use of rituximab in paediatric nephrology

Rajiv Sinha et al.

Summary: Rituximab is a chimeric monoclonal antibody that can deplete B cells, originally used in oncology but later found effective for rheumatological conditions and kidney diseases, and has gained significant interest in pediatric nephrology in recent years.

ARCHIVES OF DISEASE IN CHILDHOOD (2021)

添加到收藏夹

Review Rheumatology

Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease

Jeffrey A. Sparks et al.

Summary: Although literature on COVID-19 outcomes in immune-mediated inflammatory disease patients has been generally reassuring, there are still many unanswered questions. Individual factors such as glucocorticoid use and disease activity are associated with severe COVID-19 outcomes, while specific medications like tumor necrosis factor inhibitors and rituximab have varying associations. Studies also offer important insights into antibody response after COVID-19 vaccination for patients with immune-mediated inflammatory diseases.

CURRENT OPINION IN RHEUMATOLOGY (2021)

添加到收藏夹

Article Pediatrics

X-Linked Agammaglobulinemia Presenting as Neutropenia: Case Report and an Overview of Literature

Mosopefoluwa Lanlokun et al.

Summary: Early evaluation for primary humoral immune deficiency in male patients under 12 months with neutropenia can help avoid unnecessary bone marrow biopsy in stable cases.

FRONTIERS IN PEDIATRICS (2021)

添加到收藏夹

Article Hematology

Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma

Jonathan C. Strefford et al.

Summary: This study demonstrates that Fc gamma R genotype is not associated with response to rituximab/obinutuzumab plus chemotherapy in treatment-naive patients with advanced FL or DLBCL.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Hematology

Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment

Malgorzata Nowicka et al.

Summary: The study suggests that higher FCGR2B expression in DLBCL patients can reduce drug efficacy and is associated with shorter progression-free survival in R-CHOP treatment. High FCGR2B expression may promote responsiveness to R-CHOP treatment compared to G-CHOP treatment.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Rheumatology

Hypogammaglobulinemia after rituximab for rheumatoid arthritis is not rare and is related with good response: 13 years real-life experience

Gerasimos Evangelatos et al.

Summary: The study found that 43% of rheumatoid arthritis patients treated with RTX developed HGG. Patients who developed low IgG or low IgM had lower baseline levels than those who did not, and the development of low IgM was associated with better disease outcomes.

RHEUMATOLOGY (2021)

添加到收藏夹

Article Allergy

Rituximab Unveils Hypogammaglobulinemia and Immunodeficiency in Children with Autoimmune Cytopenia

Giorgio Ottaviano et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)

添加到收藏夹

Article Rheumatology

Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy

Alice Combier et al.

RHEUMATOLOGY (2020)

添加到收藏夹

Review Immunology

Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia

Khalaf Kridin et al.

AUTOIMMUNITY REVIEWS (2020)

添加到收藏夹

Review Rheumatology

Effects of rituximab therapy on B cell differentiation and depletion

L. Bergantini et al.

CLINICAL RHEUMATOLOGY (2020)

添加到收藏夹

Letter Clinical Neurology

Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature

Chiara Zanetta et al.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2020)

添加到收藏夹

Article Immunology

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab

Sonia Boyer-Suavet et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Article Allergy

A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia

Isabella Quinti et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)

添加到收藏夹

Review Immunology

Hepatitis B Virus Reactivation Potentiated by Biologics

Eiichi Ogawa et al.

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2020)

添加到收藏夹

Article Hematology

Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19

Thomas Hueso et al.

BLOOD (2020)

添加到收藏夹

Article Medicine, General & Internal

Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus

Lennard Ostendorf et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Immunology

Management of PTLD After Hematopoietic Stem Cell Transplantation: Immunological Perspectives

Francesca Compagno et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Letter Allergy

Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma

Haoli Jin et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)

添加到收藏夹

Review Neurosciences

Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab

Despoina Florou et al.

BRAIN SCIENCES (2020)

添加到收藏夹

Article Immunology

Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients

Laura S. van Dam et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Review Hematology

Management of Epstein-Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation

Li Liu et al.

THERAPEUTIC ADVANCES IN HEMATOLOGY (2020)

添加到收藏夹

Article Biophysics

Early and late hematologic toxicity following CD19 CAR-T cells

Shalev Fried et al.

BONE MARROW TRANSPLANTATION (2019)

添加到收藏夹

Review Immunology

B cells in chronic graft-versus-host disease

William McManigle et al.

HUMAN IMMUNOLOGY (2019)

添加到收藏夹

Review Rheumatology

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

Antonis Fanouriakis et al.

ANNALS OF THE RHEUMATIC DISEASES (2019)

添加到收藏夹

Article Medicine, General & Internal

Rituximab-induced IgG hypogammaglobulinemia in children with nephrotic syndrome and normal pre-treatment IgG values

Pierluigi Marzuillo et al.

WORLD JOURNAL OF CLINICAL CASES (2019)

添加到收藏夹

Article Pediatrics

Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases

Amer M. Khojah et al.

PEDIATRIC RHEUMATOLOGY (2019)

添加到收藏夹

Review Immunology

Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders

Celine Kaegi et al.

FRONTIERS IN IMMUNOLOGY (2019)

添加到收藏夹

Review Hematology

Preventing infectious complications when treating non-malignant immune-mediated hematologic disorders

Luis Malpica et al.

AMERICAN JOURNAL OF HEMATOLOGY (2019)

添加到收藏夹

Review Immunology

B cell targeted therapies in autoimmune disease

Jennifer L. Barnas et al.

CURRENT OPINION IN IMMUNOLOGY (2019)

添加到收藏夹

Article Rheumatology

Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis

Tamara H. Ramwadhdoebe et al.

RHEUMATOLOGY (2019)

添加到收藏夹

Article Rheumatology

Long-Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five-Year Observational Study

Kevin L. Winthrop et al.

ARTHRITIS CARE & RESEARCH (2019)

添加到收藏夹

Article Rheumatology

Autologous hematopoietic stem cell transplantation in systemic sclerosis induces long-lasting changes in B cell homeostasis toward an anti-inflammatory B cell cytokine pattern

Michael Gernert et al.

ARTHRITIS RESEARCH & THERAPY (2019)

添加到收藏夹

Review Clinical Neurology

B-Cell Therapy for Multiple Sclerosis: Entering an Era

Ariele L. Greenfield et al.

ANNALS OF NEUROLOGY (2018)

添加到收藏夹

Review Hematology

A tale of two antibodies: obinutuzumab versus rituximab

Ciara L. Freeman et al.

BRITISH JOURNAL OF HAEMATOLOGY (2018)

添加到收藏夹

Article Immunology

Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors

Tobias Alexander et al.

EUROPEAN JOURNAL OF IMMUNOLOGY (2018)

添加到收藏夹

Review Immunology

Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution

Keith A. Sacco et al.

IMMUNOTHERAPY (2018)

添加到收藏夹

Review Immunology

Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment

Isabelle Meyts et al.

JOURNAL OF CLINICAL IMMUNOLOGY (2018)

添加到收藏夹

Article Rheumatology

Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus - distinct roles of BAFF and APRIL

I. Parodis et al.

LUPUS (2018)

添加到收藏夹

Article Medicine, General & Internal

Primary Sjogren's Syndrome

Xavier Mariette et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Rheumatology

Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Andrew I. Rutherford et al.

RHEUMATOLOGY (2018)

添加到收藏夹

Article Rheumatology

Switched Memory B Cells Are Increased in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis and Their Change Over Time Is Related to Response to Tumor Necrosis Factor Inhibitors

Emiliano Marasco et al.

ARTHRITIS & RHEUMATOLOGY (2018)

添加到收藏夹

Review Immunology

CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity

Edward A. Clark et al.

FRONTIERS IN IMMUNOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Rituximab and Fibrillary Glomerulonephritis: Interest of B Cell Reconstitution Monitoring

Claire Leibler et al.

JOURNAL OF CLINICAL MEDICINE (2018)

添加到收藏夹

Article Clinical Neurology

Monitoring B-cell repopulation after depletion therapy in neurologic patients

Erik Ellwardt et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2018)

添加到收藏夹

Article Medicine, General & Internal

Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia

Sara Barmettler et al.

JAMA NETWORK OPEN (2018)

添加到收藏夹

Review Medicine, Research & Experimental

A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies

Kensei Tobinai et al.

ADVANCES IN THERAPY (2017)

添加到收藏夹

Review Immunology

Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab

Evangelos A. A. Christou et al.

INTERNATIONAL REVIEWS OF IMMUNOLOGY (2017)

添加到收藏夹

Review Allergy

Update on the use of immunoglobulin in human disease: A review of evidence

Elena E. Perez et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)

添加到收藏夹

Article Medicine, Research & Experimental

B cell repertoires in HLA-sensitized kidney transplant candidates undergoing desensitization therapy

John F. Beausang et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2017)

添加到收藏夹

Article Rheumatology

Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples

Venkat Reddy et al.

RHEUMATOLOGY (2017)

添加到收藏夹

Review Chemistry, Medicinal

Current perspective on rituximab in rheumatic diseases

Tommaso Schioppo et al.

DRUG DESIGN DEVELOPMENT AND THERAPY (2017)

添加到收藏夹

Article Immunology

B cell phenotypes in patients with rheumatoid arthritis relapsing after rituximab: expression of B cell-activating factor-binding receptors on B cell subsets

E. Becerra et al.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2017)

添加到收藏夹

Review Medicine, Research & Experimental

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience

Gilles Salles et al.

ADVANCES IN THERAPY (2017)

添加到收藏夹

Article Urology & Nephrology

Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome

Shuichiro Fujinaga et al.

CLINICAL NEPHROLOGY (2016)

添加到收藏夹

Article Immunology

Features of Human CD3+CD20+ T Cells

Elisabeth Schuh et al.

JOURNAL OF IMMUNOLOGY (2016)

添加到收藏夹

Article Rheumatology

Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus Pooled Analyses From the Phase III Belimumab Trials

Ronald F. van Vollenhoven et al.

ARTHRITIS & RHEUMATOLOGY (2016)

添加到收藏夹

Article Hematology

Antiviral prophylaxis in patients with solid tumours and haematological malignancies-update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)

Michael Sandherr et al.

ANNALS OF HEMATOLOGY (2015)

添加到收藏夹

Review Immunology

The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus

Thomas Doerner et al.

AUTOIMMUNITY REVIEWS (2015)

添加到收藏夹

Letter Allergy

Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab-for how long?

Sara Barmettler et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)

添加到收藏夹

Article Immunology

Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease

Darren M. Roberts et al.

JOURNAL OF AUTOIMMUNITY (2015)

添加到收藏夹

Article Immunology

Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: A case series

Darren M. Roberts et al.

JOURNAL OF AUTOIMMUNITY (2015)

添加到收藏夹

Article Rheumatology

Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years

Ronald F. van Vollenhoven et al.

JOURNAL OF RHEUMATOLOGY (2015)

添加到收藏夹

Article Oncology

Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study

Federico De Angelis et al.

LEUKEMIA RESEARCH (2015)

添加到收藏夹

Review Oncology

Immunreconstitution and Infectious Complications After Rituximab Treatment in Children and Adolescents: What Do We Know and What Can We Learn from Adults?

Jennifer Worch et al.

CANCERS (2015)

添加到收藏夹

Article Hematology

Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity

Andrew T. Vaughan et al.

BLOOD (2014)

添加到收藏夹

Article Orthopedics

The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease

Helena Marco et al.

BMC MUSCULOSKELETAL DISORDERS (2014)

添加到收藏夹

Article Immunology

Antibody Deficiency Secondary to Chronic Lymphocytic Leukemia: Should Patients be Treated with Prophylactic Replacement Immunoglobulin?

Fatima Dhalla et al.

JOURNAL OF CLINICAL IMMUNOLOGY (2014)

添加到收藏夹

Article Medicine, General & Internal

Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes

M. Makatsori et al.

QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2014)

添加到收藏夹

Article Surgery

A Single Dose of Rituximab Does Not Deplete B Cells in Secondary Lymphoid Organs but Alters Phenotype and Function

E. G. Kamburova et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2013)

添加到收藏夹

Article Hematology

Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial

Corey Cutler et al.

BLOOD (2013)

添加到收藏夹

Article Hematology

Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia

Sif Gudbrandsdottir et al.

BLOOD (2013)

添加到收藏夹

Article Hematology

Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens

DeepakBabu Chellapandian et al.

BRITISH JOURNAL OF HAEMATOLOGY (2013)

添加到收藏夹

Article Oncology

Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections

Carla Casulo et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)

添加到收藏夹

Article Oncology

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

Sylvia Herter et al.

MOLECULAR CANCER THERAPEUTICS (2013)

添加到收藏夹

Article Rheumatology

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

Ronald F. van Vollenhoven et al.

ANNALS OF THE RHEUMATIC DISEASES (2012)

添加到收藏夹

Article Medicine, General & Internal

Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma

C. Keane et al.

INTERNAL MEDICINE JOURNAL (2012)

添加到收藏夹

Article Rheumatology

Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics

Inmaculada De La Torre et al.

RHEUMATOLOGY (2012)

添加到收藏夹

Article Hematology

Rituximab resistance

Andrew R. Rezvani et al.

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2011)

添加到收藏夹

Article Hematology

The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab

Manfred Ahlgrimm et al.

BLOOD (2011)

添加到收藏夹

Review Infectious Diseases

Does rituximab increase the incidence of infectious complications? A narrative review

Theodoros Kelesidis et al.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2011)

添加到收藏夹

Article Immunology

Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab

Luca Bologna et al.

JOURNAL OF IMMUNOLOGY (2011)

添加到收藏夹

Article Clinical Neurology

Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab

H. L. Pellkofer et al.

NEUROLOGY (2011)

添加到收藏夹

Review Hematology

Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms

Daniel Tesfa et al.

EXPERT REVIEW OF HEMATOLOGY (2011)

添加到收藏夹

Letter Hematology

Rituximab-induced late onset neutropenia in newly-diagnosed B-cell lymphoma correlates with Fc receptor Fc gamma RIIIa 158(V/F) polymorphism

Szu-Chin Li et al.

AMERICAN JOURNAL OF HEMATOLOGY (2010)

添加到收藏夹

Article Rheumatology

Risk Factors for Severe Infections in Patients With Rheumatoid Arthritis Treated With Rituximab in the AutoImmunity and Rituximab Registry

J. -E. Gottenberg et al.

ARTHRITIS AND RHEUMATISM (2010)

添加到收藏夹

Article Rheumatology

Immunization Responses in Rheumatoid Arthritis Patients Treated With Rituximab Results From a Controlled Clinical Trial

Clifton O. Bingham et al.

ARTHRITIS AND RHEUMATISM (2010)

添加到收藏夹

Editorial Material Hematology

A gut feeling about plasmablasts

David Tarlinton

BLOOD (2010)

添加到收藏夹

Article Hematology

Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity

Jacek Bil et al.

BLOOD (2010)

添加到收藏夹

Article Hematology

Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab

Henrik E. Mei et al.

BLOOD (2010)

添加到收藏夹

Article Rheumatology

Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials

Ronald F. van Vollenhoven et al.

JOURNAL OF RHEUMATOLOGY (2010)

添加到收藏夹

Article Medicine, General & Internal

Late-Onset Neutropenia After Rituximab Treatment Case Series and Comprehensive Review of the Literature

Ofir Wolach et al.

MEDICINE (2010)

添加到收藏夹

Article Rheumatology

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

C. Salliot et al.

ANNALS OF THE RHEUMATIC DISEASES (2009)

添加到收藏夹

Article Oncology

Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis

Sercan Aksoy et al.

LEUKEMIA & LYMPHOMA (2009)

添加到收藏夹

Article Rheumatology

Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response

Magda Nakou et al.

ARTHRITIS RESEARCH & THERAPY (2009)

添加到收藏夹

Article Medicine, General & Internal

Rituximab and intravenous immune globulin for desensitization during renal transplantation

Ashley A. Vo et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

添加到收藏夹

Article Multidisciplinary Sciences

Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice

Jean-David Bouaziz et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)

添加到收藏夹

Article Hematology

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism

Evdoxia Hatjiharissi et al.

BLOOD (2007)

添加到收藏夹

Article Medical Laboratory Technology

Rare-event analysis in flow cytometry

Albert D. Donnenberg et al.

CLINICS IN LABORATORY MEDICINE (2007)

添加到收藏夹

Article Immunology

B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny

Jennifer H. Anolik et al.

CLINICAL IMMUNOLOGY (2007)

添加到收藏夹

Article Hematology

Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma

Mitsufumi Nishio et al.

EUROPEAN JOURNAL OF HAEMATOLOGY (2006)

添加到收藏夹

Article Rheumatology

Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab

M Tokunaga et al.

RHEUMATOLOGY (2005)

添加到收藏夹

Article Hematology

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

MS Cragg et al.

BLOOD (2003)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.